论文部分内容阅读
对３２例活动期强直性脊柱炎（ＡＳ）患者给予柳氮磺胺吡啶（Ｓｕｌｆａｓａｌａｚｉｎｅ，ＳＳＺ）治疗３～２３月（第１周１．０／ｄ，第２周起２．０／ｄ维持），分别于服药后３月、６月及１年以上复查７项活动性指标（关节疼痛数、关节肿胀数、晨僵时间、扩胸度、Ｓｃｈｏｂｅｒ试验、ＥＳＲ及ＣＲＰ）。观察结果，治疗后除扩胸度以外的各项指标均显著改善；服药１年以上者临床缓解率显著高于服药３月或６月者；药物副作用多发生于服药３月内，本组患者无１例因副作用停药。结果表明ＳＳＺ对活动期ＡＳ患者具有肯定疗效，足够疗程与适当剂量对提高疗效具有重要意义。坚持服用ＳＳＺ（２．０／日）１年以上既可获得较高的临床缓解率又具有良好安全性。
32 patients with active ankylosing spondylitis (AS) were treated with sulfasalazine (SSZ) for 3 to 23 months (1.0 / d in the first week and 2.0 / d in the second week) Seven active indicators (joint pain, joint swelling, morning stiffness, chest enlargement, Schober test, ESR and CRP) were reviewed at 3 months, 6 months and over 1 year after taking the medicine. Observations, after treatment, except for the expansion of the index were significantly improved; taking more than 1 year clinical remission rate was significantly higher than those taking March or June; drug side effects occurred in taking medication within 3 months, the patients None of the patients discontinued due to side effects. The results show that SSZ patients with active AS have a positive effect, adequate treatment and appropriate dose to improve the efficacy of great significance. Adhere to take SSZ (2.0 / day) for more than 1 year can get a higher clinical remission rate and has good safety.